Gartner to Present at the BofA Securities 2022 Information Services Conference

Gartner, Inc. (NYSE: IT) announced that Craig Safian, Executive Vice President and CFO, will present at the BofA Securities 2022 Information Services Conference.

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/09/2022 - 08:00 AM EST

STAMFORD, Conn.--(BUSINESS WIRE)-- Gartner, Inc. (NYSE: IT) today announced that Craig Safian, Executive Vice President and Chief Financial Officer, will present at the BofA Securities 2022 Information Services Conference.

Gartner’s presentation is scheduled for 10:35 am ET on Thursday, March 17, 2022. A link to the live webcast of the presentation will be available via the Company's web site at http://investor.gartner.com. A replay of the webcast will be available for approximately 30 days following the presentation.

About Gartner

Gartner, Inc. (NYSE: IT) delivers actionable, objective insight to executives and their teams. Our expert guidance and tools enable faster, smarter decisions and stronger performance on an organization’s mission critical priorities. To learn more, visit gartner.com.

Source: Gartner, Inc.
Gartner-IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005092/en/

David Cohen
GVP, Investor Relations, Gartner
+1 203.316.6631

Kathleen Persaud
Sr. Director, Investor Relations, Gartner
+1 203.316.1672

investor.relations@gartner.com

Source: Gartner, Inc.

Keep reading

More on IT

All IT news

Trending in the feed

AARD

Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials Open the live feed